Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management

@article{Hamidi2019MetastaticPA,
  title={Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management},
  author={Oksana Hamidi},
  journal={Current Opinion in Endocrinology & Diabetes and Obesity},
  year={2019},
  volume={26},
  pages={146–154}
}
  • Oksana Hamidi
  • Published 2019
  • Medicine
  • Current Opinion in Endocrinology & Diabetes and Obesity
  • Purpose of review Metastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL. Recent findings Latest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors… CONTINUE READING
    9 Citations
    Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview
    Targeting Pheochromocytoma/Paraganglioma with polyamine inhibitors.

    References

    SHOWING 1-10 OF 68 REFERENCES
    Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    • 134
    • PDF
    Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
    • 55
    • PDF
    Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
    • 87
    • PDF
    SDHB mutation carriers with malignant pheochromocytoma respond better to CVD.
    • 16
    • PDF
    Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    • 135
    Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma
    • 58